Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma

肝外胆管癌患者的肿瘤浸润炎症和免疫细胞

阅读:12
作者:Yuki Kitano, Hirohisa Okabe, Yo-Ichi Yamashita, Shigeki Nakagawa, Yoichi Saito, Naoki Umezaki, Masayo Tsukamoto, Takanobu Yamao, Kensuke Yamamura, Kota Arima, Takayoshi Kaida, Tatsunori Miyata, Kosuke Mima, Katsunori Imai, Daisuke Hashimoto, Yoshihiro Komohara, Akira Chikamoto, Takatoshi Ishiko, Hid

Background

Inflammation and immune characteristics of the tumour microenvironment have therapeutic significance. The

Conclusions

Our data showed that tumour infiltrating inflammatory and immune cells may play a pivotal role in ECC progression and a high-risk signature predicted poor prognosis in ECC patients.

Methods

A total of 114 consecutive ECC patients with curative resection between 2000 and 2014 were enrolled. Tumour infiltrating CD66b+ neutrophils (TANs; tumour associated neutrophils), CD163+ M2 macrophages (TAMs; tumour associated macrophages), CD8+ T cells, and FOXP3+ regulatory T cells (Tregs) were assayed by immunohistochemistry, and their relationships with patient clinicopathological characteristics and prognosis were evaluated.

Results

Tumour associated neutrophils were inversely correlated with CD8+ T cells (P=0.0001) and positively correlated with Tregs (P=0.001). High TANs (P=0.01), low CD8+ T cells (P=0.02), and high Tregs (P=0.04) were significantly associated with poor overall survival (OS). A high-risk signature, derived from integration of intratumoural inflammatory and immune cells, was significantly associated with poor recurrence-free survival (P=0.01) and OS (P=0.0008). A high-risk signature was correlated with postoperative distant metastases. Furthermore, a high-risk signature was related to the resistance to gemcitabine-based chemotherapy used after recurrence. Conclusions: Our data showed that tumour infiltrating inflammatory and immune cells may play a pivotal role in ECC progression and a high-risk signature predicted poor prognosis in ECC patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。